BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Riordan W, McManus A, Teras J, Poromanski I, Cruz-Saldariagga M, Quintas M, Lawrence L, Liang S, Cammarata S; PROCEED Study Group. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study. Clin Infect Dis 2018;67:657-66. [PMID: 29518178 DOI: 10.1093/cid/ciy165] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Dagher M, Fowler VG Jr, Wright PW, Staub MB. A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay? Open Forum Infect Dis 2020;7:ofaa151. [PMID: 32523971 DOI: 10.1093/ofid/ofaa151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, Holland TL, Fowler VG Jr. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol 2019;17:203-18. [PMID: 30737488 DOI: 10.1038/s41579-018-0147-4] [Cited by in Crossref: 281] [Cited by in F6Publishing: 236] [Article Influence: 140.5] [Reference Citation Analysis]
3 Voulgaris GL, Voulgari ML, Falagas ME. Developments on antibiotics for multidrug resistant bacterial Gram-negative infections. Expert Rev Anti Infect Ther 2019;17:387-401. [PMID: 31006284 DOI: 10.1080/14787210.2019.1610392] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
4 Giordano PA, Pogue JM, Cammarata S. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis 2019;68:S223-32. [PMID: 30957167 DOI: 10.1093/cid/ciz006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Vlachaki I, Vacchelli M, Zinzi D, Falla E, Jiang Y, Mantopoulos T, Nathwani D. Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis. BMC Infect Dis 2021;21:1036. [PMID: 34610820 DOI: 10.1186/s12879-021-06736-x] [Reference Citation Analysis]
6 Liapikou A, Cilloniz C, Palomeque A, Torres T. Emerging antibiotics for community-acquired pneumonia. Expert Opin Emerg Drugs 2019;24:221-31. [PMID: 31657962 DOI: 10.1080/14728214.2019.1685494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
7 Sutton JD, Carico R, Burk M, Jones MM, Wei X, Neuhauser MM, Goetz MB, Echevarria KL, Spivak ES, Cunningham FE; Skin and Soft Tissue Infection Medication Use Evaluation Group . Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation. Open Forum Infect Dis 2020;7:ofz554. [PMID: 32010738 DOI: 10.1093/ofid/ofz554] [Reference Citation Analysis]
8 Miller LG. Another New Antibiotic for Skin Infections and Why Infectious Disease Specialists Are Hypocrites. Clinical Infectious Diseases 2019;68:1223-4. [DOI: 10.1093/cid/ciy720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bassetti M, Melchio M, Giacobbe DR. Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. Expert Rev Anti Infect Ther 2021;:1-8. [PMID: 34913817 DOI: 10.1080/14787210.2021.2020098] [Reference Citation Analysis]
10 Iregui A, Khan Z, Malik S, Landman D, Quale J. Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, New York. Clin Infect Dis 2020;70:1758-60. [PMID: 31412357 DOI: 10.1093/cid/ciz787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Lodise T, Corey R, Hooper D, Cammarata S. Safety of Delafloxacin: Focus on Adverse Events of Special Interest. Open Forum Infect Dis 2018;5:ofy220. [PMID: 30349845 DOI: 10.1093/ofid/ofy220] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
12 Bassetti M, Labate L, Melchio M, Robba C, Battaglini D, Ball L, Pelosi P, Giacobbe DR. Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Expert Opin Pharmacother 2021;:1-14. [PMID: 34882041 DOI: 10.1080/14656566.2021.2010706] [Reference Citation Analysis]
13 Crass RL, Pai MP. Estimating Renal Function in Drug Development: Time to Take the Fork in the Road. J Clin Pharmacol 2019;59:159-67. [PMID: 30184267 DOI: 10.1002/jcph.1314] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
14 Davis K, Greenstein T, Viau Colindres R, Aldridge BB. Leveraging laboratory and clinical studies to design effective antibiotic combination therapy. Curr Opin Microbiol 2021;64:68-75. [PMID: 34628295 DOI: 10.1016/j.mib.2021.09.006] [Reference Citation Analysis]
15 Bassetti M, Peghin M, Castaldo N, Giacobbe DR. The safety of treatment options for acute bacterial skin and skin structure infections. Expert Opin Drug Saf 2019;18:635-50. [PMID: 31106600 DOI: 10.1080/14740338.2019.1621288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
16 Ma YX, Wang CY, Li YY, Li J, Wan QQ, Chen JH, Tay FR, Niu LN. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections. Adv Sci (Weinh) 2020;7:1901872. [PMID: 31921562 DOI: 10.1002/advs.201901872] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 18.3] [Reference Citation Analysis]
17 Pai MP, Crass RL. Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses. Antibiotics (Basel) 2021;10:1368. [PMID: 34827306 DOI: 10.3390/antibiotics10111368] [Reference Citation Analysis]
18 Chahine EB, Dougherty JA, Thornby KA, Guirguis EH. Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance? Ann Pharmacother 2021;:10600280211031390. [PMID: 34259076 DOI: 10.1177/10600280211031390] [Reference Citation Analysis]
19 Yahav D, Tau N, Shepshelovich D. Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant Bacteria. Clin Infect Dis 2021;72:1968-74. [PMID: 32337578 DOI: 10.1093/cid/ciaa457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Hatlen TJ, Miller LG. Staphylococcal Skin and Soft Tissue Infections. Infect Dis Clin North Am 2021;35:81-105. [PMID: 33303329 DOI: 10.1016/j.idc.2020.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Eckmann C, Tulkens PM. Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics. J Antimicrob Chemother 2021;76:iv9-iv22. [PMID: 34849999 DOI: 10.1093/jac/dkab351] [Reference Citation Analysis]
22 Shortridge D, Pfaller MA, Streit JM, Flamm RK. Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014-2019). J Glob Antimicrob Resist 2020;23:278-83. [PMID: 33068780 DOI: 10.1016/j.jgar.2020.09.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Golan Y. Current Treatment Options for Acute Skin and Skin-structure Infections. Clin Infect Dis 2019;68:S206-12. [PMID: 30957166 DOI: 10.1093/cid/ciz004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
24 Bassetti M, Righi E, Pecori D, Tillotson G. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. Future Microbiol 2018;13:1081-94. [PMID: 29764190 DOI: 10.2217/fmb-2018-0067] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Giacobbe DR, Labate L, Vena A, Bassetti M. Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. Curr Opin Infect Dis 2021;34:109-17. [PMID: 33395093 DOI: 10.1097/QCO.0000000000000708] [Reference Citation Analysis]
26 Scott LJ. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections. Drugs 2020;80:1247-58. [PMID: 32666425 DOI: 10.1007/s40265-020-01358-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
27 Nascimento-Carvalho CM. Delafloxacin as a treatment option for community-acquired pneumonia infection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34346823 DOI: 10.1080/14656566.2021.1957098] [Reference Citation Analysis]
28 Fabre V, Sharara SL, Salinas AB, Carroll KC, Desai S, Cosgrove SE. Does This Patient Need Blood Cultures? A Scoping Review of Indications for Blood Cultures in Adult Nonneutropenic Inpatients. Clin Infect Dis 2020;71:1339-47. [PMID: 31942949 DOI: 10.1093/cid/ciaa039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
29 Fan KC, Lin J, Yannuzzi NA, Al-Khersan H, Patel NA, Maestre-Mesa J, Zaidi M, Miller D, Flynn HW Jr. In vitro Susceptibilities of Methicillin-Susceptible and Resistant Staphylococci to Traditional Antibiotics Compared to a Novel Fluoroquinolone. J Ophthalmic Inflamm Infect 2020;10:9. [PMID: 32103368 DOI: 10.1186/s12348-020-0200-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Prentice C, Quach S, Thaichon P. Antecedents and consequences of panic buying: The case of COVID‐19. Int J Consum Stud. [DOI: 10.1111/ijcs.12649] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 10.0] [Reference Citation Analysis]
31 Bassetti M, Hooper D, Tillotson G. Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis 2019;68:S233-40. [PMID: 30957169 DOI: 10.1093/cid/ciy1080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Kollef MH, Betthauser KD. New antibiotics for community-acquired pneumonia. Curr Opin Infect Dis 2019;32:169-75. [PMID: 30640820 DOI: 10.1097/QCO.0000000000000526] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
33 Saravolatz LD, Stein GE. Delafloxacin: A New Anti–methicillin-resistant Staphylococcus aureus Fluoroquinolone. Clinical Infectious Diseases 2019;68:1058-62. [DOI: 10.1093/cid/ciy600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
34 Chao CM, Weng TS, Chen YH, Lai CC, Lin WT. Anti-MRSA quinolones for acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34753366 DOI: 10.1080/14787210.2022.2004119] [Reference Citation Analysis]
35 Wittke F, Vincent C, Chen J, Heller B, Kabler H, Overcash JS, Leylavergne F, Dieppois G. Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid. Antimicrob Agents Chemother 2020;64:e00250-20. [PMID: 32747361 DOI: 10.1128/AAC.00250-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Shiu J, Ting G, Kiang TK. Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin. Eur J Drug Metab Pharmacokinet 2019;44:305-17. [PMID: 30324277 DOI: 10.1007/s13318-018-0520-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
37 Wang TZ, Kodiyanplakkal RPL, Calfee DP. Antimicrobial resistance in nephrology. Nat Rev Nephrol 2019;15:463-81. [PMID: 31086308 DOI: 10.1038/s41581-019-0150-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
38 Nicola F, Azula N, Santoni G, Smayevsky J. [In vitro activity of delafloxacin against bacterial isolates from osteoarticular and skin infections in Buenos Aires, Argentina]. Rev Argent Microbiol 2021:S0325-7541(21)00047-X. [PMID: 34053809 DOI: 10.1016/j.ram.2021.02.012] [Reference Citation Analysis]
39 Motos A, Yang H, Yang M, Torres A. Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia. Expert Opin Pharmacother 2019;20:1439-48. [PMID: 31095426 DOI: 10.1080/14656566.2019.1617852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Millar BC, Mccaughan J, Rendall JC, Moore JE. Delafloxacin––A novel fluoroquinolone for the treatment of ciprofloxacin‐resistant Pseudomonas aeruginosa in patients with cystic fibrosis. Clin Respir J 2021;15:116-20. [DOI: 10.1111/crj.13262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Jaffa RK, Pillinger KE, Roshdy D, Isip JA, Pasquale TR. Novel developments in the treatment of acute bacterial skin and skin structure infections. Expert Opinion on Pharmacotherapy 2019;20:1493-502. [DOI: 10.1080/14656566.2019.1617851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
42 Al-Tawfiq JA, Momattin H, Al-Ali AY, Eljaaly K, Tirupathi R, Haradwala MB, Areti S, Alhumaid S, Rabaan AA, Al Mutair A, Schlagenhauf P. Antibiotics in the pipeline: a literature review (2017-2020). Infection 2021. [PMID: 34606056 DOI: 10.1007/s15010-021-01709-3] [Reference Citation Analysis]
43 Andrei S, Valeanu L, Chirvasuta R, Stefan MG. New FDA approved antibacterial drugs: 2015-2017. Discoveries (Craiova) 2018;6:e81. [PMID: 32309599 DOI: 10.15190/d.2018.1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
44 Vrancianu CO, Dobre EG, Gheorghe I, Barbu I, Cristian RE, Chifiriuc MC. Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms 2021;9:730. [PMID: 33807464 DOI: 10.3390/microorganisms9040730] [Reference Citation Analysis]
45 O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E; OASIS-2 Investigators. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 2019;19:1080-90. [PMID: 31474458 DOI: 10.1016/S1473-3099(19)30275-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 8.3] [Reference Citation Analysis]
46 Lan SH, Lai CC, Lu LC, Chang SP, Huang HT. Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials. Infect Drug Resist 2019;12:1415-23. [PMID: 31213859 DOI: 10.2147/IDR.S202160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Saravolatz LD, Pawlak JM, Wegner C. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid. Journal of Antimicrobial Chemotherapy 2020;75:2605-8. [DOI: 10.1093/jac/dkaa209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]